近日,博鳌未来医院官方公众号发布公告称,诺和诺德长效生长激素——帕西生长激素注射液作为临床急需药物被引入乐城博鳌未来医院后,截至目前,该药已惠及20余例年龄在4.5至14.5岁之间的生长激素缺乏症(GHD)患儿,随访显示,他们在3个月内身高增长达到3-4 cm,为我国GHD患儿提供了新的治疗选择。帕西生长激素注射液则采用了一项在国际上已有36年应用历史的成熟技术——脂肪酸衍生化制药技术。该技术对...
Source Link近日,博鳌未来医院官方公众号发布公告称,诺和诺德长效生长激素——帕西生长激素注射液作为临床急需药物被引入乐城博鳌未来医院后,截至目前,该药已惠及20余例年龄在4.5至14.5岁之间的生长激素缺乏症(GHD)患儿,随访显示,他们在3个月内身高增长达到3-4 cm,为我国GHD患儿提供了新的治疗选择。帕西生长激素注射液则采用了一项在国际上已有36年应用历史的成熟技术——脂肪酸衍生化制药技术。该技术对...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.